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ABSTRACT
Inducing a Normal Phenotype in Breast Epithelial Cells Using a ThreeDimensional Basement Membrane Extract Culture System:
A Study on the Reversion of Cancer
by
Ross H. Booth, Master of Science
Utah State University, 2009
Major Professor: Dr. Soonjo Kwon
Department: Biological and Irrigation Engineering
Experimentally, traditional developmental models and transgenic animals
consistently underscore the importance of studying cell behavior in the correct tissue
context. However, live animal experimentation is inherently complex, and systematic
assessment of the effects of individual variables, such as cell shape and matrix compliance
on cell behavior, is extremely difficult at best. Two-dimensional monolayer culture of key
individual cell types has provided abundant, fundamental information on cell response, but
cannot be used to show the normal phenotype of breast epithelial cells. Furthermore, their
results often fail to translate into in vivo and clinical studies. It has been previously
established that normal human breast epithelial cells can form their original phenotype as
seen in vivo when embedded in or layered on reconstituted basement membrane extract.
This phenotype is characterized as a single or double layer of polarized cells in acinar form
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with a lumen devoid of cells. Most malignant cell lines cultured under the same conditions
exhibit severe morphological deformities, including colony overgrowth, luminal filling
(hyperplasia), and resistance to apoptosis. It was hypothesized that malignant breast cells
can be reverted to a normal phenotype through the manipulation of two factors: control of
the environment via extra-cellular matrix proteins, and control of cellular pathways via
signaling inhibitors. It was observed that high levels of epidermal growth factor resulted in
disrupted multi-acinar formations. Inhibition of the protein complex known as mammalian
target of rapamycin is currently being investigated as a potential method for cancer
treatment. Exposure of rapamycin, mammalian target of rapamycin’s primary inhibitor, led
to decreased proliferation and increased caspase activity. Through the exposure to
rapamycin in three-dimensional cultures, proliferation was reduced in malignant cells,
while normal cells were not significantly affected. Unfixed fluorescent staining with
ethidium bromide indicated the presence of luminal cell death.

Increased structural

organization was observed by immunofluorescent staining of F-actin and β-catenin.
Through RT-PCR analysis, increased expression of a number of genes related to polarity
and structural organization was detected in malignant cells exposed to rapamycin. Further
study will be required to better characterize the reversion effects of rapamycin and its
derivatives.
(74 pages)
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PREFACE

•

Note that the term malignant is used frequently in this paper. The term “malignant”
is often used to describe tumors that have ceased to be benign and have become
invasive. In this paper (and much of the cited literature) the term malignant is
intended to refer to all cancer cells.
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CHAPTER 1
INTRODUCTION

The history of cancer research, as young as it is, has gone through rapid changes in
a short period of time. As new causes for cancer have been discovered throughout the 20th
century - from the Rous Sarcoma Virus in 1910 to the first proto-oncogene in 1975 and the
now hundreds of suspect carcinogens being rigorously investigated – the focus of cancer
researchers has constantly been changing direction. As cancer ascends to become the
world’s leading cause of death, the fierce debate over where researchers should focus their
attention continues. While most traditional studies of cancer focus primarily on the
signaling, chemistry, and genetics of individual cancer cells, a growing movement of
researchers has been publishing work asserting that tissue microenvironmental influences
should be held coequal. For many, adopting this perspective has required them to take a
unique approach to cancer research, but history has shown that exploring new paths of
inquiry can be productive to scientific progress.

1.1 Achieving Physiological Accuracy in Cellular Models
The case for the importance of cell-based in vitro models needs little persuasion. Before
clinical studies can begin, the concept in question must be well established in laboratory
studies. While animal models can be very useful, in vitro models are often preferred due to
ethical, technical, and financial constraints. In addition, a greater amount of experimental
control is allotted to the researcher using cell-based models. For this reason there has been
a very high demand for effective cell-based models in cancer research [1].
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However, for a cellular model to be useful, it must properly represent conditions
found in vivo. One of the advantages of human cell-based models over animal studies is
that the researcher can avoid complications from species-dependent concepts. There
remains an advantage for animal models in that they address a higher level of complexity
which existing cellular models do not have. This level of complexity must be addressed in
cellular models to overcome this advantage.

1.1.1

Adding an Extra Dimension
Cytotoxic agents and tumor suppressors tested successfully on two-Dimensional

(2D) plastic cultures often fail to translate successfully into in vivo research. This resistance
to signaling factors is also sometimes present in three-dimensional (3D) culture systems
[2]. This presents a real issue for 2D cultures, as they fail to address this resistance to drugs
which is often present in actual tissues.
Accurate cell differentiation and functionality often has 3D spatial requirements [3],
and the polarized phenotype that epithelial cells possess in vivo is rarely observed in 2D
cultures. Breast cancers are subdivided into at least 18 distinct subtypes [4], each with
unique histological properties. These can be difficult to differentiate visually from
appearance on a plastic monolayer, but these differences are better visually recognized
when placed in 3D culture models (Figure 1). Even the differences between normal and
cancer cells can be difficult to distinguish in 2D, while easily characterized when placed in
3D cultures.
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Figure 1: Normal Cells Cultured in 2D and 3D on Day 6 of Culture
ulture
The difference between morphologies of cells cultured in 2D and 3D are clear. Monolayer
cultures adhere to the plastic surface and reach confluence, while the same cells cultured in
3D will spread 3-dimensionally
dimensionally and limit their growth. (scale bars = 25 µm)

1.1.2 Experimental Control
There is an inverse correlation between model complexity and experimental
control. Therefore, a balance must be found between maximizing model complexity and
maintaining control over experimental design. To simplify,, controllable factors have been
lumped into twoo classes: signal molecules and microenvironment. The importance of the
microenvironment
environment has often been understated as excitement over the discovery of
oncogenes has led researchers to focus their attention on genetic mutation as the cause of
cancer and metastasis. However, data contradictory to the somatic mutation theory [5] has
allowed new theories to be proposed. These theories suggest that research should be
looking not only for intracellular targets, but also at the interactions between cancer cells
and their microenvironment.
environment.
The microenvironment
environment includes the 3D arrangement of the cells themselves,
themselves as well
as the surrounding extra
extra-cellular matrix (ECM). The ECM is not
ot merely a structural
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scaffold, but directly affects a series of intracellular pathways which modify the expressed
phenotype in a variety of ways [6]. A reciprocal interaction between tissue architecture and
gene expression is strongly supported [7] and will be discussed in the following section.

1.1.3 Mechanisms of Microenvironmental Impact on Phenotype
Two broad hypotheses were proposed in a recent review article which effectively
asserts the importance of the microenvironment in cancer development.
First, that tumour cells with abnormal genomes should be capable of
becoming phenotypically normal if their normal microenvironment can be restored,
and, secondly (and conversely), that the destruction of tissue structure itself could
be an oncogenic event, even in the absence of initial genetic mutation. [8]
Indeed, bolder advocates of the 3D method suggest that tissues are constantly being
bombarded with oncogenic factors, and that the proper maintenance of tissue architecture
and polarity is a sole factor preventing oncogenesis [3, 9]. There are two general methods
through which the ECM directs cell pathways. The first is directly through membranebound receptors on the exterior cells, and the second is through other pathways which are
indirectly dependent on morphology [10]. The mechanisms through which epithelial cells
receive cues from the surrounding ECM have been studied extensively. The most well
established mechanism is through membrane-bound integrins [11].
Cells in a dynamic human body are constantly undergoing physical forces. These
forces include shear stress, compression and tension forces, and hydrostatic pressure. Cells
have mechanisms for detecting these forces, and they can have a major effect on cellular
pathology, including cancer. The loss of tensional homeostasis can increase cancer risks
and compromise treatment [12, 13]. Culturing in 3D is associated with an increase in global
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histone acetylation [14], which results in chromatin condensation and a decrease in cell
proliferation.
Matrix metallo-proteinases (MMPs) are ECM-degrading proteins which are often
dispatched into the stroma [15]. Epithelial mesenchymal transition (EMT), a phenotypic
alteration in which epithelial cells detach from their neighbors and the underlying basement
membrane and become more motile and migratory, which has profound effects on tumor
metastasis, is known to be induced by pathways including MMPs. However, this process
has been shown to be limited by changes in cell shape [16]. Another recent study
measuring the branching locations of metastasizing cells using micropatterning found that,
remarkably, branch sites were located only on tubule corners [8], indicating a dependency
on tissue architecture.

1.1.4 The Functional Unit
One primary difference between 3D and 2D culture models is the functional unit.
Traditionally the functional unit was the individual cell, but in 3D cultures the functional
unit is the entire structure the cells form [17]. As a result, a greater amount of criteria can
be investigated on a single functional unit which couldn’t before, such as tissue polarity,
cell-cell communication, multicellular structure, and localization of function.
Identification of the functional unit is a first step in experimental design. In the case
of breast cancer, the mammary acinus is the unit of interest, and is characterized by a
spherical formation consisting of a single layer of epithelial cells surrounding an empty
lumen. The purpose of the lumen in ducts is to carry milk proteins to the branching
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locations and ultimately the nipple. The development of ducts from alveoli is led by a
complex differentiation process which is still poorly understood [18]. The process of
alveolar branching and the generation of ducts has been observed to be dependent upon
communication with the ECM surroundings [19]. These cells go through differentiation
many times through the life of the individual, including periods such as puberty and
lactation. Perhaps this is why the breast is so vulnerable to cancer.
In most cell lines, the structure forms from a single cell over a period of 6-10 days
(Figure 2) in 3D culture. The precise mechanisms are not well understood, but the cells
begin to polarize, leading to survival of outer cells, and death of luminal cells.

Figure 2: Formation of the Mammary Gland Acinus in vitro
The functional unit for human breast epithelial cells is a spherical acinus consisting
of an outer layer of cells and a lumen devoid of cells. In culture, polarization of the
outer cells leads to apoptosis of un-polarized cells in the center [9].
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1.1.5 ECM and Basolateral Polarity
A unique characteristic of epithelial cells is their ability to functionally polarize.
The membrane-bound proteins and biochemical activity on each (basal and luminal) side
are different in polarized cells. For example, in the breast acinus, the activity on the luminal
side includes cues which incite apoptosis on interior cells, and the activity on the basal side
includes interaction with the basement membrane. Myoepithelial cells, while normally
present in vivo, are normally left out of these cultures. This is because their functional role
in polarity appears to be maintenance of the basement membrane [20]. Luminal formation
is still poorly understood, but is mostly likely caused by induced apoptosis of interior cells
separated from the exterior layer. As this only happens in the presence of a polarized outer
layer, a signal is likely being transmitted from the luminal edge of the exterior cells which
is initiating terminal pathways [21].
As early as the 1970s, the importance of the basement membrane and basolateral
polarity in structural development of healthy tissues was being discussed [22], and normal
polarity was achieved using ECM-based gels in culture as early as 1992 [23]. Choice of
ECM is not only important because it provides physical support and special freedom for
acinar formation; it promotes cell polarity. However, basal cells are only responsive to the
correct ECM recipe. While collagen is the most commonly found ECM protein in the body
and is commonly used in tissue engineering, polarity has been found to be preserved best
when using proteins which closely resemble the basement membrane [24]. The mixture
derived commercially from the Engelbroth-Holm Swarm (EHS) tumor, better known as
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reconstituted basement membrane extract (rBME), was found experimentally to be the best
option and is still used today.
The primary component in rBME is laminin-I, which has been found to directly
induce higher integrin activity and better adhesion in preadipocyte cells [25]. Laminin-I is
also known to be have a strong role in early tissue organization of embryos in the womb
[26]. Other components of rBME include procollagen IV, heparin sulfate proteoglycan, and
entactin [27]. It is likely that all these basement membrane components play a role in
directing an optimal phenotype, though these roles are still not well characterized. Still,
laminin is believed to be the most important component [28].

1.2 Previous Studies
Table 1 lists several signal molecules which have been investigated using 3D
culture models. In vivo, tumor cells lose some or all of their morphological organization in
healthy tissue. Using 3D cultures as introduced in the previous section, cancer cells can be
studied through morphological observation. In 2D, normal and malignant cells similarly
form adherent monolayers, but when placed in 3D rBME, the difference becomes clear.
Morphological disruptions are present in the malignant cultures just as they are in vivo.
Through the manipulation of signal molecules, malignant cultures can be reverted back to a
normal phenotype. This is commonly termed a reversion strategy.
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Table 1: Previous Studies Using 3D Culture Models
Manipulation of the phenotype of normal and malignant cells cultured in 3D can provide
valuable insight into cell communication pathways, and potential causes and treatments of
cancer.
Pathway
Rap1 GTPase
β1-integrin

cAMP
PI3K Kinase

EGFR,
MAPK
PI3K Kinase
ErbB2
Insulin-like
growth factor

Description of Results
Found to be crucial in organizing acinar structure and inducing lumen
formation. Inhibition of Rap1 led to phenotypic reversion. [29]
Inhibition of β1-integrin with blocking antibodies led to significan loss of
cancer cell proliferation, increased apoptosis. Re-organized cytoskeletons.
Non-malignant cells were resistant to any change. [30-32]
cAMP analogues increased malignant cells’ sensitivity to AluI digestion,
and to revert the structures to normal polarity. [33]
Inhibition of PI3K reverted tissue polarity and decreased proliferation. Led
to down-modulation of β1-integrin and EGFR, and up-regulation of
PTEN. [34]
Reversion and reduced malignant behavior, decreased proliferation and
increased polarity. [31]
Normal cells with mutations to PI3K exhibit severe morphological
deformities. [35]
ErbB2, but not ErbB1, reinititates proliferation and induces luminal
repopulation in epithelial acini. [36]
Type I insulin-like growth factor receptor overexpression led to large
misshapen structures with filled lumena and disrupted polarization. [37]

It’s been shown using 3D rBME cultures that regardless of growth status, in both
malignant and nonmalignant mammary epithelial cells, the presence of the basement
membrane provides protection from apoptosis. This suggests that integrin-induced polarity
drives tumor-cell resistance to apoptotic agents via NFkB [38]. More specifically, the
formation of polarized acini are dependent on the activity of α6 and β1 surface integrins, in
combination with the presence of laminin-I [39]. Researchers have found a reciprocal
cross-modulation between β1-integrin and EGFR which was not present in 2D cultures.
This cross-modulation was attributed to being dependent on the presence of the basement
membrane [40]. Experimentation with 3D cultures has led to the conclusion that apoptosis
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must be restrained through resistance pathways for the lumen to become populated [41]. It
was also found that luminal formation in rBME cultures required carcinoembryonic
antigen—related cell adhesion molecule (CEACAM), to be present a high levels. This
suggests that the morphogenic program integrates both cell-cell and cell-ECM signaling to
produce the lumen [42]. The importance of MMP activity on branching morphogenesis was
successfully demonstrated using 3D rBME cultures [43]. Similar in vitro models have been
developed for other cell types, including skin, prostate, muscle, colon, bile duct, esophagus,
adipocytes, fibroblasts, and embryonic stem cells [4]. Some of them are being used to study
the same groups of pathways as well. For example, the disruption of the PI3K pathway has
been found to have a similarly profound impact on the morphogenesis of epithelial acini in
prostate cancer [44].

1.3 Mammalian Target of Rapamycin
To attempt to induce a normal phenotype for malignant cells, it was desired to
select a compound with a great foundation of literary support to justify its selection, but
also to design an original experiment. Rapamycin is the primary inhibitor for the
mammalian target of rapamycin (mTOR) pathway. In a study using a non-cancerous breast
epithelial cell line cultured in 3D with rBME, activation of the Akt kinase caused the cells
to form morphologically disrupted structures with amplified proliferation. Inhibition with
rapamycin completely reversed this malignant behavior [45]. Though rapamycin and other
mTOR inhibitors are being investigated as cancer drugs, the effectiveness of mTOR
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inhibition as a reversion strategy for breast cancer cell
ell lines using rBME cultures appears to
be unexplored. These
ese are the reasons rapamycin
apamycin was chosen for this study.

1.3.1 History of Use
Rapamycin was identified in the mid-1970s
1970s as a potent antifungal agent and was
found to be a potent suppressor of the immune system. It was FDA approved in 1999 for
use under the drug name Sirolimus as an immunosuppressive drug. Its immunosuppressive
mechanism is derived from its inhibitory effect on the progression of T-cells
T
from G1phase into S phase [46].. Rapamycin is also being used to treat liver cirrhosis, and has
proven effective in improvement of liver function in rat models, even in low doses [47]. Its
structure is displayed in Figure 3. Its development as a cancer therapy has been far slower
because of formulation and stability concerns in producing a parenteral formulation [48].

Figure 33: Structure of Rapamycin (Sirolimus)
Figure was released to Wikipedia.org as public domain.
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In a study utilizing 3D rBME-embedded culture models, Akt activation elicited
large, misshapen structures with enhanced proliferation and increased cell size. However,
mTOR inhibition by rapamycin was shown to completely cancel these effects [49]. This
study was the primary source for the selection of rapamycin as an exposure factor for
reversion.

1.3.2 The Akt – mTOR Tango and Other Cancer Pathways
The serine/threonine kinase Akt (also known as PKB) is known to have at least
three major impacts on cancer progression: proliferation, survival, and cell growth. For this
reason, it is one of the most intensively studied pathways in breast cancer research. Downregulation of Akt has been seen to inhibit anchorage-independent cell growth and induce
apoptosis in various cancer cell lines [50]. Akt inactivates the downstream protein BAD,
which normally promotes cell apoptosis in non-polarized cells [51]. PTEN, a tumor
suppressor gene whose activity inhibits Akt phosphorylation, can be inhibited by mTOR.
Therefore mTOR inhibition leads to PTEN upregulation, and hence Akt suppression [52].
The complex pathway web which includes mTOR, Akt, PI3K, and PTEN has been
found to have various functions, including cell progression, angiogenesis, and resistance to
apoptosis [53, 54]. Currently, rapamycin-chemotherapy pre-clinical combination studies
are being conducted on mouse models to investigate rapamycin’s effect on PI3K-induced
cancers [55]. In prostate cells, doxorubicin resistance was reversed by rapamycin [56].
Rapamycin has been shown to reverse chemoresistance in lymphomas expressing Akt [57].
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The effects of statins on Akt signaling was found only to be effective when used in
combination with rapamycin [58].
The effects of mTOR on cancer pathways are not limited to Akt. Rapamycin
exposure on mice was found to increase the levels of nitric oxide synthase in inflammatory
responses. These effects appeared to be caused by mechanisms other than Akt [59],
suggesting that mTOR has effects on other signal cascades. Rapamycin-induced inhibition
of mTOR has been shown to inhibit MMP-7 production in mouse models [60], and MMP-9
has also been shown to be reduced by rapamycin exposure [61]. Increased MMP
production is known to lead to breakdown of the ECM in many cases. In glioma cell lines,
MMP-1, MMP-2, and MMP-9 was downregulated after treatment with rapamycin [62].
Inhibition of mTOR was found to have no effect on sensitivity to radiation therapy
on glioblastoma cells when conducted in a monolayer, but was greatly increased when
applied in vivo [63]. This further illustrates the importance of 3D cultures, while building
the case for rapamycin as a cancer drug. Rapamycin exposure has also been shown to
suppress tumor growth by anti-angiogenic suppression of vascular endothelial growth
factor (VEGF) production [64]. In acute lymphoblast leukemia cells, rapamycin induced
apoptosis and increased doxorubicin-induced apoptosis in many samples analyzed [65].
Cell proliferation tests demonstrated that rapamycin enhanced cell sensitivity to endocrine
therapy in breast cancer cells [66].
Two distinct protein complexes are known to bind to mTOR: Raptor and Rictor.
The mTOR-Raptor complex is exclusively downstream from Akt, while the mTOR-Rictor
complex has a feedback mechanism by which it enhances Akt activity through PI3K and
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PTEN. In effect, mTOR acts both downstream and upstream from Akt [67] in the signaling
cascade. This is one very interesting aspect of the mTOR pathway, in that inhibiting it
undoubtedly has multiple effects on cellular pathways.

1.4 Hypothesis & Aims
From the preceding literature review, the following hypothesis was formulated:
Malignant cells, cultured in 3D rBME and exposed to rapamycin, can be forced to revert to
a normal phenotype. Phenotypic reversion criteria include:
1. Decreased proliferation – smaller, growth-arrested colonies
2. Structural organization – spherical structures with increased multi-cellular
organization and an ordered cytoskeleton
3. Polarization – increased interaction with the basement membrane and luminal
formation in the center of the colonies
To conduct this experiment, two primary aims were developed:
1. Establishment of normal phenotype of normal cells cultured in 3D rBME as a
positive control through optimization of culture conditions
2. Observing the effects of rapamycin on the phenotype of malignant cells cultured in
3D rBME.with comparisons to normal cells
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CHAPTER 2
METHODOLOGY

There are two primary methods for conducting 3D culture with rBME gels. The
first, embedded, involves fully embedding cells in a thick layer of gel, while the second,
on-top,
top, involves laying cells on
on-top
top a thin layer of gel while slowly adding additional gel in
the media at low concent
concentrations.
rations. Both methods allow 3D structure formation, but the onon
top method has two advantages
advantages. First, it uses significantly less materials.. Second,
S
it lays all
colonies into approximately the same horizontal plane. This makes image analysis
significantly easier.
sier. For this study, only 3D on
on-top was used (Figure 4). For more detailed
descriptions of methods used, see Appendix A.

Figure 4: 3D on-top Method of Cell Culture
Individual cells are initially seeded on
on-top
top reconstituted rBME gels and supplemented with
media containing 2-10%
10% rBME v/v. Gel slightly thickens over time as more rBME is added
every 2 days, and colonies grow into acini.
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2.1 Cell Culture
Malignant breast epithelial cells (BT-483, MDA-MB-468) and normal breast
epithelial cells (184-B5) were purchased from ATCC (VA). For monolayer culture, BT483 was cultured using RPMI-1640 (Sigma-Aldrich, MO) with 20% fetal bovine serum
(FBS) (Thermo Fisher Scientific, UT) and 0.01 mg/mL bovine insulin, MDA-MB-468 was
cultured using Leibovitz’s L-15 Media (Sigma-Aldrich) with 10% FBS in air with no
added CO2, and 184-B5 was cultured using MEGM (Lonza, Switzerland) with 1 ng/mL of
cholera toxin and without gentamycin-amphotericin-B.
To achieve luminal morphology, cells were cultured using 3D on-top assays as
previously described [68, 69]. The cultrex 3D culture matrix (Trevigen, MD) rBME
product was chosen because it was specifically formulated for breast epithelial cell cultures
and is modified to contain reduced growth factors and is phenol red free. Assay media was
modified to contain 2-10% BME, with 2% FBS for malignant cells and with or without
EGF (Epidermal Growth Factor) supplements for normal cells. All media was
supplemented with 1% Penicillin/Streptomycin (Invitrogen, CA) and 0.1% Fungizone
(Hyclone, UT). Cell cultures were seeded at 0.25x105 (184-B5), 0.22x105 (BT-483), and
0.18x105 (MDA-MB-468) cells/cm2. Assay media was changed every two days subsequent
to seeding. Rapamycin (Sigma-Aldrich, MO) was reconstituted in DMSO and stored at 20°C at a stock concentration of 1 µM.
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2.2 Morphological Observation
Morphology was observed using a TE2000-S Eclipse Microscope (Nikon, Japan) or
a TS100 Eclipse Microscope (Nikon, Japan). All images were taken with a Digitial Sight
DSQi1Mc Camera (Nikon, Japan). Fluorescence images were detected with an Intensilight
C-HGFI lamp (Nikon, Japan). For the detection of non-viable (or apoptotic) cells, nonfixed cultures were incubated for 15-30 minutes with 1 µM ethidium bromide or 500 nM
propidium iodide and observed for fluorescence. Cell colonies were extracted using PBSEDTA solution, fixed using 4% paraformaldehyde, and blocked with 10% goat serum and
1% goat F(ab’) IgG (Sigma-Aldrich, MO). Monoclonal anti-actin (1A4) and monoclonal
anti-β-catenin (15B8) were obtained from Sigma-Aldrich (St. Louis, MO) for use as
primary antibodies. Secondary antibody for FITC-conjugated goat anti-mouse was obtained
from Santa Cruz Biotechnology (CA). Image analysis was conducted using NIS-Elements
v3.0 (Nikon). Areas of cell colonies (in the x-y plane) in all images were analyzed for the
calculation of mean areas under different conditions.

2.3 Caspase 3/7 Assay
Monolayers of BT-483 and 184-B5 cells were prepared in a 96-well plate to
analyze the effects of RAP on caspase activity. Caspase activity was measured at 24 and
48 hours following exposure to RAP at 0, 5, and 20 nM. Exactly 100 µL of Casapase-Glo
3/7 Reagent (Promega, WI) was added to each sample, including 2 blank wells containing
100 µL of growth media and incubated for 2 hours. Luminescence was then measured
using a Synergy 4 Plate Reader (Biotek, VT).
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2.4 Cell Viability Assay
CellTiter-Blue Cell Viability Assay reagent was obtained from Promega (WI).
MDA-MB-468 and 184-B5 cells were seeded in 96-well plates and, beginning on day two,
were treated continuously with 0 nM and 20 nM RAP. On day three and day seven, cell
viability assays were conducted and measured for fluorescence.

2.5 Real-Time RT-PCR Arrays
Human extracellular matrix and adhesion molecule-based real time reverse
transcriptase polymerase chain reaction (RT-PCR) SuperArrays were obtained from
SABiosciences (MD). MDA-MB-468 cells cultured in 3D on BME gels were treated with
0 nM and 20 nM RAP for six days. Colonies were extracted using PBS-EDTA, mRNA was
extracted using RNeasy RNA isolation kit (QIAGEN, CA), and cDNA synthesis was
conducted using the Reverse Transcriptase First Strand Kit (SABiosciences, MD). Real
time PCR arrays were run using a Bio-Rad Opticon 2 thermocycler system (MJ Research,
Canada) and analyzed using the Opticon 2 software provided. Ct values were acquired
graphically.

2.6 Statistical Analysis
With the SYSTAT 12 software, statistical analyses on all quantitative data were
carried out using one-way and two-way ANOVA (analyses of variance) to verify
statistical significance (p < 0.05).
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CHAPTER 3
RESULTS

3.1 Optimization of Culture Conditions
Using the 3D on--top method, 184-B5 (normal) cells were initially cultured in a
MEGM-based
based assay medium containing epidermal growth factor (EGF
EGF) additive, a
supplement provided with the Media kit. Cultured cells formed large, morphologically
disrupted structures with no apparent limitations to growth. Culturing
uring the cells in EGFEGF
reduced media
edia resulted in the formation of significantly smaller structures with uniformity
in shape. This effect is demon
demonstrated in Figure 5. EGF-reduced cultures appeared to reach
a maximum size by day 6 of culture. Exposure to 20 nM rapamycin had no visible effect on
EGF-induced
induced morphological distortion.

Figure 5. Effects
ffects of EGF on 3D Morphology of Normal Cells
184B5 breast epithelial cells cultured on
on-top
top BME gels with and without EGF. Top, EGFreduced assay media induce
induced a normal phenotype, including smaller, round morphology
with maximum size by day 5 of culture. Bottom, EGF-enhanced
enhanced assay media leads to
increased
ased proliferation and disrupted morphology. (Scale bars = 25 µm)
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Figure 6. Effects of Reducing EGF on Average Colony Size for Normal Cells
Average cell colony areas were measured from 184B5 breast epithelial cells cultured ontop BME gels with and without EGF on day 7 of culture. EGF-reduced colonies showed a
significantly lower average area than the EGF-enhanced colonies. (* Significantly lower
than control, Error bars + st. dev, p < 0.05)

Image analysis of average area of normal cells with and without EGF showed a
significantly lower area for EGF-reduced colonies at day 7 (Figure 6). This proves
quantitatively that EGF causes over-proliferation and prevents proper formation of the
normal phenotype.
Malignant cells cultured using the 3D on-top method grew into large,
morphologically disrupted structures. Unlike EGF reduction, FBS reduction did not lead to
a change in morphology. Subsequently, 2% FBS was used in all experiments.
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3.2 Effects of Rapamycin Exposure

3.2.1 Caspase 3/7 Activity
Figures 7 and 8 show the effects of rapamycin exposure on caspase activity in
normal (184-B5) and malignant (BT-483) breast epithelial cells. For normal cells, the only
condition which showed significant deviation fom the control was 20 nM rapamycin for 48
hours of exposure. For malignant cells, 20 nM of exposure showed a significantly higher
effect on caspase activity than 5 nM, but only at 48 hours of exposure. Caspase 3 and
caspase 7 are established markers for programmed cell death. Programmed cell death is
required for the formation of the luminal space in 3D cultures, so this data provides
evidence that rapamycin can have an effect on polarity. For raw data, see Appendix B.
+
*

6.0E+05
5.0E+05

0 nM CTRL

4.0E+05

5 nM RAP

RLUs 3.0E+05

20 nM RAP

2.0E+05
1.0E+05
0.0E+00
24 hrs

48 hrs
Exposure Time

Figure 7: Caspase 3/7 Response in Normal Cells From Rapamycin Exposure
Effect on caspase activity of normal (184-B5) breast epithelial cell monolayers at 24 and 48
hours of exposure to 0, 5, and 20 nM rapamycin. (n=2, * significantly higher than control,
+ significantly higher than 5 nM, error bars + st. dev., p <0.05)
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Figure 8: Caspase 3/7 Response in Malignant Cells From Rapamycin Exposure
Effect on caspase activity of malignant (BT-483) breast epithelial cell monolayers at 24 and
48 hours of exposure to 0, 5, and 20 nM rapamycin. (n=2, * significantly higher than
control, + significantly higher than 5 nM, error bars + st. dev., p <0.05)

3.2.2 Cell Viability Assay
Figure 9 shows the effects of 20 nM rapamycin on the total level of cell viability in
monolayer cultures of both normal (184-B5) and malignant (MDA-MB-468) cells after 2
and 6 days of continuous exposure (and one day untreated). Both cell lines (MDA-MB-468
& 184-B5) showed a significant reduction in cell proliferation with a significantly higher
reduction seen on day 7 than on day 3. This shows that Rapamycin has either a cytotoxic
effect, or that it leads to downstream regulation of the cell cycle. The caspase data
previously shown provides evidence that the latter is true. All conditions were conducted in
triplicates. Error bars show the standard deviation among the three samples, and in all
cases there is no overlap between the error bars of the control and treatment samples. This
data shows a significant change in viable cells in each of the treated samples conditions
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(p<0.05). This is quantitative supporting evidence that rapamycin limits cell proliferation,
at an increasing margin over time. For raw data, see Appendix B.
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Figure 9: Proliferation of Normal and Malignant Cells
at 2 & 6 Days of Rapamycin Exposure
Monolayer cultures of normal (184-B5) and malignant (MDA-MB-468) cells were exposed
for 2 & 6 days to 20 nM rapamycin, and analyzed for total cell viability. Levels of cell
viability were significantly lower under all conditions for rapamycin-treated cultures, by an
increasing margin over time. (n=3, * significantly lower than control, p < 0.05)

24
3.2.3 Morphological
gical Observation
Exposure with 20 nM rrapamycin
apamycin led to an average of considerably smaller sized
cell colonies, typically reaching their maximum size by day 6 (Figure 10).
10 Cell colonies
weree comparable in size and shape to normal cells. Rapamycin exposure led to significant
reduction of average cell colony area ((Figure 11) in both malignant cell lines (BT-483
(BT
&
MDA-MB-468).

Figure 10
10. Effect of Rapamycin Exposure on Malignant
Cell Morphology in 3D Culture
Rapamycin was exposed to malignant (BT
(BT-483)
483) cells beginning after one day of culture at
0 and 20 nM concentrations, and compared to normal (184
(184-B5)
B5) cells. Normal cells,
bottom,, compared in colony shape and size to rapamycin
rapamycin-treated
treated cultures, middle.
Malignant cells, top,, exhbited severe morphological disruption when cultured without
treatment. (Scale bars = 25 µm)
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Figure 11. Effects of Rapamycin Exposure on Average Cell Colony Size of
Malignant Cells on Day 7 of 3D Culture
Effects of rapamycin exposure on average cell colony size: Average cell colony areas were
measured from malignant (BT-483 & MDA-MB-468) cells continuously treated with 0 and
20 nM rapamycin Average cell colony areas (xy plane) were measured from BT-483 and
MDA-MB-468 malignant cells treated with 0 and 20 nM RAP on day 7 of 3D rBME
culture. No significant difference was found between the two cell lines, but rapamycin
treatment significantly reduced cell colony size. (Error bars + st. dev, * significantly lower
than control, p < 0.05).

Labelling of apoptotic cells was done using ethidium bromide and propidium iodide
to stain un-fixed 3D cultures of normal and malignant cells (Figure 12) at day 8 of culture.
An inner subset of cells undergoing luminal cell death (apoptosis) was observed in normal
cell colonies, as well as malignant cell colonies treated continuously with rapamycin. This
indicates the presence of lumen formation, and provides evidence that rapamycin treatment
induced the cells to exhibit polarity.
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Figure 12.. Selective Staining of Non-Viable Cells Indicates the
Presence of Luminal Apoptosis
Top: Staining of day 8 3D cultures of normal (184-B5) cells with ethidium bromide or
propidium idodie resulted in detection of cell death in the center of cell colonies.
Bottom & Middle: Similar occurences of centrally
centrally-localized
localized apoptosis were detected in
both cancer cell lines (BT
(BT-483 & MDA-MB-468) when treated continuously with 20 nM
rapamycin.. (Scale bars = 25 µm)

Structural
tructural organization was observed using anti
anti-actin
actin and anti-β-catenin
anti
immunofluorescent stains. The results are pictured in Figure 13. Cells were stained with
FITC secondary antibod
antibodies (green) and counterstained with DAPI (blue
blue).

Reverted

malignant cells and normal cells exhibited primarily spherical mu
multi-cellular
cellular colonies, while
untreated
treated malignant cells show
showed no organization. Rapamycin-treated
treated malignant colonies
exhibited cells arranged around the center
center, showing similarities to the structure of normal
cells cultured in rBME.
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Figure 13.. Immunofluor
Immunofluorescent Staining of Normal Cells and Rapamycin Treated
Malignant Cells at Day 7 of 3D Culture
Malignant (BT-483)
483) cell colonies from day 7 of culture, after continuous treatment of 20
nM rapamycin from day 2, exhibit multi
multi-cellular
cellular organization similar to day 7 cultures of
normal (184-B5) cells.
Top: Anti-actin
ctin (green) counterstained with DAPI (blu
(blue).
Bottom: Anti-β-batenin
atenin (green) counterstained with DAPI (blue). (Scale bars = 25 µm)

3.2.4 RT-PCR Arrays
rray plates containing genes related to human extracellula
xtracellular and adhesion
Two PCR array
molecules were runn together with cDNA derived from mRNA extracted from HTB-132
HTB
cells grown in rBME. One sample, as a control, was untreated. The other
oth sample was
exposed to 20 nM rapamycin
apamycin for four days after two days untreated. The PCR arrays
included six wells for positive controls and one well for a genomic DNA contamination
check. The genomic DNA con
contamination
tamination wells were both >35, which indicates that there
was no genomic DNA contamination. The standard deviation for all controls were well
below 1,, as was the difference between the average controls for the two
t
plates. The
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difference between the reverse transcription control (RTC) and the positive PCR control
(PPC) was < 5, which designates the presence of successful PCR reactions. From these
calculations, it was concluded that the data is acceptable for analysis. See appendix for raw
data and quality control analysis.
Ct values were cutoff at > 35 as undetected. Fold change of each gene was
calculated using the DDCT (∆∆Ct) and classified according to gene category (Table 2).
Data was cutoff as significant at a fold change of < 0.2 or > 5.0. See appendix for
additional tables containing genes inside the cutoff range, and genes for which no fold
change could be calculated due to a Ct value of > 35.
Twenty-five genes related to ECM & adhesion molecules showed a significant (at
least 5-fold) increase in expression, while no genes showed a significant (less than 0.2)
decrease in expression. Gene groups including basement membrane constituents and cellmatrix adhesion molecules support the presence of increased basolateral polarity in 3D
cultured malignant cells treated with 20 nM rapamycin. Gene groups including cell-cell
adhesion molecules, trans-membrane molecules, and other adhesion molecules such as
catenin support the presence of increased structural organization in 3D cultured malignant
cells treated with 20 nM rapamycin.
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Table 2. Rapamycin’s Effects on Gene Expression of Human
Extracellular Matrix and Adhesion Molecules
Fold change was calculated using the DDCT method, with GADPH as the normalizing
gene. See Appendix B for complete data.
Gene
Category
Basement
Membrane
Constituents
Cell-Cell
Adhesion

Cell-Matrix
Adhesion

Collagens &
ECM
Structural
Constituents
ECM
Protease
Inhibitors
Other
Adhesion
Molecules
Other ECM
Molecules
Transmembrane
Molecules

Symbol

Description

LAMA2
LAMA3
LAMB3
SPARC
CDH1
CTNND1
CD44
ITGA2
ITGA6
ITGAV
ITGB1
ITGB2
ITGB5
SGCE
COL1A1
COL4A2

Laminin, alpha 2
Laminin, alpha 3
Laminin, beta 3
Secreted protein, acidic, cysteine-rich
Cadherin 1, type 1, E-cadherin (epithelial)
Catenin (cadherin-associated protein), delta 1
CD44 molecule (Indian blood group)
Integrin, alpha 2
Integrin, alpha 6
Integrin, alpha V
Integrin, beta 1
Integrin, beta 2
Integrin, beta 5
Sarcoglycan, epsilon
Collagen, type I, alpha 1
Collagen, type IV, alpha 2

Fold
Change
13.77
19.05
12.57
13.64
6.40
7.13
6.95
9.84
5.26
8.99
14.30
9.27
5.48
5.25
5.79
9.77

FN1

Fibronectin 1

16.51

THBS1

Thrombospondin 1

16.02

COL12A
1
CTNNA1
CTNNB1
LAMC1
TGFBI
VCAN

Collagen, type XII, alpha 1

17.50

Catenin (cadherin-associated protein), alpha 1
Catenin (cadherin-associated protein), beta 1
Laminin, gamma 1 (formerly LAMB2)
Transforming growth factor, beta-induced, 68kDa
Versican

7.82
11.40
6.36
10.04
17.70

ITGA4

Integrin, alpha 4

5.87
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CHAPTER 4
DISCUSSION
As shown in Figure 14, normal phenotype was achieved in 3D rBME cultures
through elimination of EGF in normal cells, and through exposure to rapamycin in
malignant cells. To reach this conclusion, we applied the results to three criteria as
established in the introduction – structural organization, limited proliferation, and polarity.

Figure 114. Summary of Experimental Results
In normal cells, normal phenotyp
phenotype was achieved by removing EGF
F additive from the assay
media, leading to limited proliferation, ma
maximum
ximum cell colony size, and luminal
lumi
apoptosis.
Rapamycin limited proliferation of malignant cells and induce
induced luminal
nal apoptosis. RTRT
PCR analysis showed an increase in gene expression of many molecules important to
polarity and structural
tructural organization, including basement membrane components, cellcell
matrix adhesion molecules, and cell-cell adhesion molecules.
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Increased multi-cellular organization was observed in the anti-actin and anti-βcatenin immunostaining images. The change in shape of the colonies from amorphous to
round is the strongest evidence towards satisfying this criterion. An increase in structural
organization was also supported by an increase in expression of genes related to cell-cell
adhesion molecules and ECM structural constituents.
Limitations on proliferation were observed through morphological observation as
well, and were confirmed by the significant change in the average areas measured in 3D
cell cultures treated with rapamycin. The cell viability assay data also provided evidence of
a decrease in proliferation due to rapamycin.
Evidence of increased polarity due to rapamycin exposure was provided by the
images of apoptotic cells located in the center of several cell colonies, indicating the
formation of a lumen. The observed increase in caspase activity provides evidence that
rapamycin affects the cell cycle and forces programmed cell death. Finally, an observed
increase in expression of genes related to basement membrane constituents and cell-matrix
adhesion molecules provides additional evidence that polarization is taking place.
Both qualitative and quantitative data was gathered to support all three criteria.
Note that, in some previous studies, reversion has been concluded though only one or two
of these criteria were satisfied [1, 9, 30, 31]. Therefore, a conclusion can be made that
Rapamycin exposure, in combination with rBME surroundings and serum-reduced media,
can revert malignant cells to show a normal phenotype in 3D cultures.
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4.1 Drawbacks to the Study
While the caspase and cell viability assays provided valuable insight into the effects
of rapamycin exposure, this study would have benefited from similar data derived from 3D
cultures. Both assays were attempted on 3D cultures, but failed to yield results with
significant difference from the controls. The ECM gel may have been autofluorescing /
autoluminescing. It is also possible that the assay reagents were either being absorbed by
(or failing to penetrate) the ECM, or were reacting with the ECM. Assays which could be
conducted on cells extracted from the ECM would likely have been much more effective.
The study would also have benefited from immunostaining images with observed
localization of function. Actin and β-catenin were not specifically localized, but present all
throughout the colonies. Antibodies for molecules related to polarity, such as α6-integrin,
would likely have been observed around the periphery of the colonies. Such localization
would likely have only been possible with confocal microscopy.
Furthermore, more replicates of the RT-PCR arrays would have statistically
strengthened the gene expression data. However, great confidence is placed in
commercially distributed PCR arrays, and researchers often publish data from a single set
of PCR arrays if they come from a trusted manufacturer.
Another drawback to this study is derived from the variability between different
cell lines, which include morphological properties and nutrition requirements. A previous
study classified malignant cell lines into four main classifications by morphology, which
differ significantly in genotype [3]. The two cell lines used in this study had “mass” and
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“grape-like” morphologies, but we cannot be certain whether rapamycin exposure would be
effective on the other morphology types, “round” and “stellate”.
When initially culturing normal (184-B5) cells, growth-arrested spherical acini
were not observed. Decreasing the amount of growth factors in the media by removing the
EGF supplement prevented this. Likely, the presence of such a high level of growth factors
led to an override of pathways which limit proliferation and lead to increased cellular
cooperation and structural organization. In addition to growth factors, these cultures are
very sensitive to humidity, and dry out much easier than 2D cultures do.
While this culture system has increased complexity when compared to plasticbound monolayers, it is still profoundly simple when compared to real breast tissue. Only
one cell type, epithelial, is represented in this model, while real breast tissue contains many
other cell types, including myoepithelial cells, fibroblasts, and adipose (fat) tissue. Cocultures of adipocyte/epithelial cells have been attempted [70]. There are many challenges
in attempting such heterotypic cell cultures. Accounting for the different metabolic and
nutritional requirements would be a difficult task indeed, and would require much
experimentation to optimize. Another difficulty is that in actual tissue, cell types are
separated from each other, such as epithelial cells from stromal cells by a basement
membrane, but in co-cultures the cell types would be co-mingled. Finally, co-cultures
containing normal and malignant cells together would need methods to control the ratios of
cells, as they may grow at different rates [4].
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4.2 Future Direction
Rapamycin has shown evidence of phenotypic reversion, but it is not the only
mTOR inhibitor. Rapamycin is actually a poor parenteral drug, due to its poor water
solubility and limited stability. Three analogues have been developed with improved
pharmaceutical properties: CCI-799 (tensirolimus), RAD-001 (everolimus) and AP-23573
(deforolimus, ARIAD). All three are more effective orally and are currently under drug
trials [71, 72]. These derivatives should also be investigated for their effectiveness as
reversion factors [52].
In addition, it would to be interesting to observe the effects of combining
rapamycin with other signal molecules to see their combined or synergistic effects on
reversion of breast cancer cells [73]. Such combination strategies for reversion have been
done many times before [9]. Rapamycin’s synergistic effects with paclitaxel, carboplatin,
and vinorelbine have been observed in a few breast cancer lines in vitro [53]. Mullerian
inhibiting substance (MIS) has also been tested with rapamycin as a dual strategy for
fighting ovarian cancer. Additive effects on MIS’s protein targets were observed [74] and
assumed to be synergistic. The additive effects of combined exposure with doxorubicin and
gemcitabine synergistically enhanced chemotherapy-induced cytotoxicity in breast cancer
cells [75]. These studies suggest that doxorubicin, paclitaxel, carboplatin, vinorelbine,
gemcitabine, and MIS would be valuable candidates for such a combination strategy.
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Three-dimensional cultures could be used to observe the mechanical properties of
normal and malignant breast cells. Such studies are currently being conducted [12, 76], and
can have far-reaching new insights on the development of tumors, including potential new
methods of treatment. If oncogenic behavior can be induced by applying external
mechanical forces, it would give valuable insight into the importance of tissue
microenvironment on tumor progression [8].
Surgeons attempting breast-conservation therapy (BCT) for breast cancer patients
would benefit greatly from an effective device for the detection of cancerous tissue in
margins of extracted tumors, and the frequency of remission cases would be drastically cut.
Ultrasound detection provides a promising option: it is relatively cheap and noninvasive
[77]. Currently, mathematical models exist which attempt to explain patterns of cell
configurations utilizing the single cell as the basic unit [78]. Testing indicates that as few as
300 malignant cells in a tissue sample can be detected [79]. The model takes advantage of
the fact that malignant cells have significantly larger nuclei than normal cells. A distinct
correlation between the size of the nuclei and integrated backscatter coefficient values has
been found through experimentation. In addition, apoptotic cells affect ultrasound readings
[80]. This is likely due to the destructive interference resulting from greater randomization
of cell nuclei [81].
Three-dimensional co-cultures of normal and malignant cells should be developed
for testing these ultrasound models. However, there are challenges involved. First, a
uniformly distributed numerical model may not translate properly into a tissue sample or a
cell-based model. In actual tissue, and in these cultures, there is little uniformity, due to the
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complex architecture these cells arrange. Numerical models being proposed include both
ordered lattices and randomized microstructures [82] to address this issue, but exactly how
these numerical models will fare when applied to gel models will depend on several
conditions. It should first be confirmed that the normal cells being used in the co-culture
have significantly smaller nuclei than the malignant cells. If accurate measurement shows
that the immortalized cell line used in this study also possesses enlarged nuclei, it may be
better to acquire primary cells for use in co-culture. The second issue is whether the cell
ratio can be easily controlled in a co-culture. It is already established from this study that
cultures of one cell type can be controlled through modification of growth factors and other
additives in the media, and through growth inhibitors such as rapamycin. However, the
control of one cell type may lead to negative side effects on the other cell type, especially
when the cell lines use different media. A promising side effect which was noticed during
this study was that normal cells appeared unaffected by rapamycin when in 3D culture.
This suggests that rapamycin may be a useful control factor for co-cultures.

4.3 Conclusion
In this study, the effects of rapamycin exposure on the phenotypic reversion of
malignant breast epithelial cell lines were investigated using a 3D rBME culture system.
Microscopic observation of malignant 3D cell cultures treated with rapamycin showed
greater similarities in morphology to normal cell cultures than in untreated malignant
cultures. Comparison of the average horizontal areas of untreated and rapamycin-treated
malignant cell colonies confirmed that rapamycin-treated malignant cell colonies are
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significantly smaller in size. Increased structural organization was observed by
immunofluorescent staining of anti-actin and anti-β-Catenin. On day 8 of 3D rBME
cultures, rapamycin-treated malignant cells stained with ethidium bromide showed similar
occurrences of luminal cell death to that observed in normal cultures, indicating repolarization of the epithelial cell layer. Supporting data from monolayer cultures indicated
that levels of caspase activity was increased in the presence of rapamycin, and that
proliferation over time was decreased. Gene expression analysis of rapamycin-treated
malignant cells from 3D culture indicated an increase in the expression of several ECM or
adhesion molecules important to polarity and structural organization. This collection of
data supports our hypothesis that RAP exposure can revert malignant breast epithelial cells
to a normal phenotype.
Our study has provided data supporting the value of mTOR inhibition as a potential
anti-tumor strategy. To provide further insight into mTOR inhibition, two further directions
of research should be taken: additional studies on the effects of other mTOR inhibitors on
phenotypic reversion, and combination studies to investigate the synergistic or combined
effects of mTOR inhibition with other cancer targets.
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APPENDIX A
LABORATORY PROTOCOLS
MAINTENANCE OF BREAST CANCER CELL LINES
I recommend adding 10 mL of Pen-Strep & 1 mL of Fungizone to every 500 mL of Media

CRL-8799 (or 184B5)
•

Non-cancer epithelial cell line, 21-year-old female

•

Cells reach confluence in 3-5 days, growth spreads very rapidly

•

Media: Use Mammary Epithelial Growth Medium (MEGM) from Clonetics.
o Comes in a kit with MEBM & a series of supplements.
o Do not add gentamycin-amphotericin B for CRL-8799 cells.
o Save ¼ of the media, and exclude the EGF additive.


This media is to be used for 3D assays.

o Also supplement all media with 1 ng/ml cholera toxin.
o Serum Free
•

Cytoprotectant media contains 10% FBS & 5% DMSO.

•

Cell growth and size is considerably lower when other media type is used.

•

Optimum Seeding Density: Standard or 1x10^4 cells/mL

•

Resistant to Trypsin-EDTA; Might take up to 15 minutes to come off plastic
without mechanical force.
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HTB-132 (or MDA-MB-468)
•

Mammary gland adenocarcinoma cells (epithelial) 51-year-old female

•

Cells reach confluence in 3-5 days, grows very rapidly. Cells tend to stack and bud
off into the media, so frequent washing is recommended.

•

Media: Use Leibovitz’s L-15 Medium.
o Complete by adding 10% FBS
o Save ¼ of the original media, and only add 2% FBS.


This media is to be used for 3D assays.

o Important: Cells grown in L-15 Media MUST be incubated in pure air.


Using enhanced CO2 levels will reduce viability.

o RPMI-1640 can be used if the previous note is impossible.
•

Cytoprotectant media contains 10% FBS & 5% DMSO.

•

Optimum Seeding Density: Standard or 1x10^4 cells/mL

HTB-121 (BT-483)
•

Mammary gland ducatal carcinoma cells (epithelial) 23-year-old female

•

Cells are very sensitive to pH, temperature & humidity – Take good care

•

Cell growth is patchy and slow; will probably never reach confluence.

•

Media: Use RPMI-1640 formulated with:
o 2 mM L-glutamine
o 10 mM HEPES
o 1 mM sodium pyruvate
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o 4.5 g/L glucose
o 1.5 g/L sodium bicarbonate


Then, to prepare for culture supplement with:

o 20% FBS
o 0.01 mg/ml bovine insulin
o Save ¼ of the original media, and only add 2% FBS.


This media is to be used for 3D assays.

•

Cytoprotectant media contains 20% FBS & 5% DMSO.

•

Optimum Seeding Density: High or 2.5x10^4 cells/mL

3D CULTURE PROCEDURE (on-top protocol)
1. Thaw the BME overnight at 4°C.
a. Aliquot if many freeze-thaws are to be conducted.
b. Keep the BME tube on ice at ALL times.
2. Pre-chill the plate(s) or dish(es) to be used in a freezer.
3. Make the assay media by mixing cold media with BME (EHS) to between 2 and
10%. Lower concentration promotes more growth & vice versa.
a. Also, lower concentrations of FBS (2-5%) may be desirable.
4. Follow Table 3 below for Gel Coat & Medium volumes.
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Table 3: Recommended Gel Culture Parameters
If the well area listed in the table is different from the wells you are using, volumes
should be adjusted. [68]
Type

# of
Wells

Dish
Plates

6
24
48
96

Diameter (mm)
60
35
16
10
6

Area
(cm2)
28.3
9.6
2
0.75
0.26

Media Volume
(µL)
5,000
2,000
500
200
60

EHS coat
(µL)
850
500
120
80
15

5. Coat the wells with the EHS coat volume and spread evenly with pipette tip.
a. Be careful to avoid bubbles – it will dry that way.
b. Due to the meniscus effect, there may be a bare spot in the center. If this is
a problem, use a little extra gel.
6. Let the gels set for 15-20 minutes at 37°C.
7. Prepare the cells to be plated by diluting to the Medium volume in assay medium.
(following the table above)
a. A good seeding density to start with is 0.2x10^5 cells/cm^2 and 0.25x10^5
cells/cm^2 for malignant and normal cells.
8. Pipette evenly over the gels & incubate at 37°C.
9. Change assay media every 2 days.
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3D EXTRACTION PROCEDURE (on-top protocol)
This protocol is for extraction of colonies from the gels without disrupting the cells
themselves.
1. Make a stock solution of PBS-EDTA:
a. 5 mM EDTA, 1 mM NaVO4, 1.5 mM NaF in PBS
2. Prepare Ice cold PBS & PBS-EDTA
3. Aspirate the media and rinse with ice-cold PBS 2 times.
a. Note that all steps need to be done at 2-8°C.
4. Add 2-3 media volumes of PBS-EDTA.
5. Gently detach the gel by scraping with a pipette tip.
6. Shake gently for 15-30 min.
a. If in-well imaging is the desired endpoint you can stop here, allow the cells
to settle to the bottom and fix.
7. Transfer the contents to a tube, and rinse the wells with 0.5 media volume and
transfer the rinse to the tube. Shake the tube (on ice) for 15-30 min.
a. If transferring colonies to slides for imaging, centrifuge at minimum speed
for 1-2 minutes, and carefully pipette 20 µl of colonies to slide.
b. For protein or RNA extraction, additional washing with PBS-EDTA and recentrifugation and re-suspension will reduce contaminating BME.
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IMMUNOSTAINING PROCEDURE
Reference these 2 papers: [68, 69] These steps are for 96-wells or slides.

Reagents
•

PBS Glycine: 100 mM Glycine in PBS

•

IF Buffer: 0.2 % Triton, 0.1% BSA, 0.05% Tween 20 in PBS, 7.7 mM NaN3

•

IF Block: 10% Goat Serum, 1% goat F(ab’) IgG in IF Buffer

1. Fixation method depends on the antibody. This may include Formalin (Room
Temp), Paraformaldehyde (RT), or 50/50 Methanol/Acetone (-20°C).
a. I’ve had good results with 4% Paraformaldehyde for 15 minutes.
2. Rinse with PBS-Glycine 3x for 10 minutes.
3. Incubate in 100 µl of IF Block for 1.5 hours (use Parafilm for slides)
4. Stain with Primary antibody in 100 µl of IF Buffer for 2 hours or overnight at 28°C. Check product info for recommended concentrations of antibody.
5. Wash 3x for 20 min in IF Buffer.
6. Stain with Secondary antibody in 100 µl of IF Buffer for 45 minutes.
7. Wash for 20 min with IF Buffer.
8. Wash 2x for 10 min in PBS.
9. Counterstain Nuclei with DAPI or Ethidium Bromide for 5 minutes.
10. Wash with PBS for 10 minutes.
11. Observe and troubleshoot if needed.
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RT PCR PROTOCOL (using SABiosciences PCR Arrays)
RNA Extraction (using QIAGEN RNeasy kit)
1. Sterilize all workspace and instruments by wiping down with RNase-away.
2. Acquire cell pellet in a centrifuge tube, and remove its supernatant.
3. Add 1 volume of Buffer RLT, and vortex the pellet.
a. For <5x10^6 cells use 350 ul, otherwise, use 600 ul
4. Continue vortexing continuously for 1 minute.
5. Add 1 volume of 70% ethanol and mix well by pipetting.
a. Remember to use ONLY RNase-free water.
6. Transfer to an RNeasy spin column and centrifuge for 15 s at 8000 g (max speed)
7. OPTIONAL DNase step
a. Add 350 ul Buffer RW1 and spin for 15 s at max speed.
b. In a separate tube, add 10 ul about 30 ku/ul DNase stock to 70 ul Buffer
RDD
c. Add all 80 ul to column and incubate at RT for 15 min
d. Add 350 ul Buffer RW1 and spin at max speed.
8. Add 700 ul Buffer RW1 and spin 15 s at max speed.
9. Add 500 ul Buffer RPE and spin 15 s at max speed.
10. Add 500 ul Beffer RPE and spin 2 min at max speed.
11. Switch to new collection tube and spin for 1 min at max speed.
12. Switch column to final collection tube for elution.
13. Add 30-50 ul RNase-free water and spin for 1 min at max speed.
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14. OPTIONAL: repaeat step 13 to increase yield of eluted RNA.
15. RNA can be stored at -80 C.

RNA Analysis
1. First quantify RNA conc. By measuring A260.
a. Remember to Blank.
b. Use conversion of 1 = 44 ug / ml
c. Concentration should be greater than 4 ug / ml
2. Check Purity by measuring 260/280 ratio.
a. 2.0-2.1 is a good ratio. (must be >2.0)
b. Also be sure the 260/230 ratio is >1.7
3. Prepare a Nano LabChip for use with an Agilent BioAnalyzer.
a. Prepare 1 ul samples of 30 ng/ul RNA.
b. 18S & 28S peaks should be sharp without shoulders or smears.
c. Alternately, a gel could be run to do this check.
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cDNA Synthesis
1. Prepare DNA Elimination Mixture by adding 2 ul 5X gDNA Elimination Buffer to
Total RNA, diluting to a total volume of 10 ul with RNase-free water.
a. Total RNA range must be between 25 ng & 5 ug.
b. Use same amount of RNA for each sample.
c. The higher the amount the better for accuracy.
2. Prepare the RT Cocktail for all samples using Table 4.

Table 4: Reverse Transcriptase Recipe
RT Cocktail
1 reaction
2 reactions
BC3 (5X RT Buffer 3)
4 ul
8 ul
P2 (Primer & External Control 1 ul
2 ul
Mix)
RE3 (RT Enzyme Mix 3)
3 ul
6 ul
Final Volume
10 ul
20 ul

4 reactions
16 ul
4 ul
12 ul
40 ul

3. cDNA Synthesis Reaction:
a. Add 10 ul of RT Cocktail to each 10 ul DNA Elimination Mixture & mix
well with pipette.
b. Incubate at 42 C for exactly 15 min and immediately stop reaction by
heating at 95 C for 5 minutes.
c. Add 91 ul of ddH20 to each 20 ul reaction tube, mix well.
4. OPTIONAL: Set aside 6 ul of the cDNA template for RNA Quality Control
Check.
5. Store template at -20 C until use.
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RT PCR STEP
1. Mix the following in a separate tube to a total Volume of 2550 ul:
a. 1275 ul 2X SABiosciences RT2 qPCR Master Mix
b. 102 ul Diluted First Strand cDNA Syntehsis Reaction
c. 1173 ul ddH2O
2. Add 25 ul of Experimental cocktail to each well of the Array Plate
3. Tightly Seal the plates with the provided 8-cap strips.
a. Tap out any bubbles that may exist in the wells.
b. Place on ice will setting up cycling program
4. Use Table 5 to set up and run the program

Table 5: RT-PCR Program
Cycles
1
40

Duration
10 minutes
15 seconds
30 – 40 seconds
30 seconds

Temperature
95 C
95 C
55 C
72 C

57
5. Use the instrument’s software to approximate the threshold cycle
a. Use the readings from cycle 2 through 2 cycle values before the earliest
visible amplication (between 10 and 15) to set the baseline.
b. Use Log View of the amp. Plots and place the threshold value within the
lower one-third to lower one-half of the linear phase.
c. Be sure the thresholds are the same across all PCR array runs. The value of
CtPPC should be 18-22 across all arrays.
d. Export the values for analysis.
6. Run a Dissociation (Melting) Curve
a. Use the instrument’s default, or run the following program:
b. 95 C, 1 min; 65 C, 2 min (OPTICS OFF); 65 C to 95 C at 2 C / min
(OPTICS ON)
7. Visually inspect the plate for any evaporation, noting specific wells.
8. Go to http://www.SABiosciences.com/pcrarraydataanalysis.php
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APPENDIX B
RAW DATA

Table 6: Caspase Data for Malignant Cells

Sample
Avg.
St. Dev

Control
7181
7321
7251
3200

Caspase Activity for BT-483 Cells
Values are in RLUs
5 nm 24 hr
5 nm 48 hr 20 nm 24 hr
18080
14372
19621
11994
14468
23288
15037
14420
21455
4303
68
2593

20 nm 48 hr
24089
24676
24383
415

Table 7: Caspase Data for Normal Cells

Sample
Avg.
St. Dev

Caspase Activity for 184-B5 Cells
Values are in RLUs
Control
5 nm 24 hr
5 nm 48 hr
20 nm 24 hr
79597
78263
75927
69469
61911
66786
74365
54926
70754
72524
75146
62197
12506
8115
1105
10283

20 nm 48 hr
271317
458742
365029
132529

Table 8: Proliferation Data for Day 3
184B5 Ctrl 184B5 Rap
7942
6654
7756
7396
8372
7746
8023.33333 7265.333
315.951473 557.6032

Values are in RFUs
MDA-MB-468 Ctrl MDA-MB-468 Rap
28022
24336
28492
25026
29419
24271
28644.33
24544.33
710.849
418.3997

Blank
14
-85
71
avg
stdev
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Table 9: Proliferation Data for Day 7
184B5 Ctrl 184B5 Rap
6135
5205
8362
5840
7535
5626
7344
5557
1125.71888 323.0743

Values are in RFUs
MDA-MB-468 Ctrl
MDA-MB-468 Rap
31703
16569
40376
22460
37569
19386
36549.33
19471.67
4425.497
2946.434

Blank
155
-214
58
avg
stdev

Table 10: Cutoff RT-PCR Fold Change Values
Gene Category

Symbol

Description

Fold Change

Basement Membrane Constituents

COL7A1

Collagen, type VII, alpha 1

3.11

Cell-Cell Adhesion

ICAM1

Intercellular adhesion molecule 1

4.20

ITGA1

Integrin, alpha 1

1.54

ITGA3

Integrin, alpha 3

2.80

ITGA5

Integrin, alpha 5

1.28

ITGB4

Integrin, beta 4

3.10

SPP1

Secreted phosphoprotein 1

2.53

COL16A1

Collagen, type XVI, alpha 1

1.02

TIMP1

TIMP metallopeptidase inhibitor 1

0.55

TIMP2

TIMP metallopeptidase inhibitor 2

2.38

ADAMTS1

ADAM metallopeptidase

3.99

MMP14

Matrix metallopeptidase 14

2.72

Cell-Matrix Adhesion

Collagens & ECM Structural
Constituents
ECM Protease Inhibitors

ECM Proteases

Other Adhesion Molecules

Other ECM Molecules

Transmembrane Molecules

SPG7

Spastic paraplegia 7

2.05

LAMB1

Laminin, beta 1

4.39

THBS2

Thrombospondin 2

4.14

TNC

Tenascin C

2.25

CTGF

Connective tissue growth factor

2.91

ECM1

Extracellular matrix protein 1

1.48

VTN

Vitronectin
Platelet/endothelial cell adhesion
molecule

0.69

PECAM1

3.73
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Table 11: RT-PCR Quality Control

Cntr.
Plate
Exp.Pla
te

Quality Control Check (Ct values)
Avg
Avg
stdev
stdev
RTC RTC
PPC
RTC
PPC
PCC

gDN
A

21.42

18.12

0.31

0.20

3.30

36.68

21.95

17.96

0.19

0.19

3.99

36.20

Table 12: Incalculable RT-PCR Data
Gene Category
Basement
Membrane
Constituents
Cell-Matrix
Adhesion
Collagens &
ECM Structural
Constituents

ECM Proteases

Other Adhesion
Molecules
Other ECM
Molecules
Transmembrane
Molecules

Symbol

Description

CTL Ct

TRT ct

+/-

LAMA1

Laminin, alpha 1

N

31.3

+

ADAMTS8

ADAM metallopeptidase

N

34.98

+

ITGA8

Integrin, alpha 8

34.19

N

-

ITGAM

Integrin, alpha M

N

34.36

+

COL6A1

Collagen, type VI, alpha 1

N

30.88

+

MMP11

Matrix metallopeptidase 11

N

32.53

+

MMP16

Matrix metallopeptidase 16

N

34.48

+

MMP3

Matrix metallopeptidase 3

N

32.07

+

MMP7

Matrix metallopeptidase 7

32.91

N

-

MMP9

Matrix metallopeptidase 9

N

33.03

+

CNTN1

Contactin 1

N

34.37

+

COL15A1

Collagen, type XV, alpha 1

30.27

N

-

KAL1

Kallmann syndrome 1 sequence

N

34.75

+

HAS1

Hyaluronan synthase 1

N

34.04

+

THBS3

Thrombospondin 3

N

31.958

+

SELL

Selectin L

N

33.211

+

VCAM1

Vascular cell adhesion molecule 1

N

34.066

+
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Table 13: Complete List of Cell Colony Areas
184-B5
w/
w/o
EGF
EGF
5119 37500
4711 24880
4419 12171
4393 15792
4299
6583
4241
6506
4013 10215
3618
6636
3574 11789
3374 13017
3346
8903
3137
7489
2946
3384
2929 15598
2855 13828
2765 42713
2593 38484
2581 28947
2548 28770
2499 28715
2386 20680
2379
2362
2272
2236
2060
1929
1820
1712
1600
1543
1101
2075
3116

Units in (µm)^2
BT-483
w/o
w/
RAP
RAP
68004
3563
44360
3472
37724
3208
22652
2927
21969
2798
16455
2667
13987
2349
12208
2307
11883
2188
10643
2062
10403
2039
8335
2014
11986
2004
30362
1980
28154
1944
17008
1930
11814
1864
6139
1790
7615
1738
1728
1711
1664
1640
1579
1570
1523
1501
1404
1350
1340
1315
1286
1277
1165

MDA-MB-468
w/o
w/
RAP
RAP
39203
2540
15722
886
11708
2324
11243
2553
18713
1505
6688
1388
4963
3070
29354
2733
10439
3000
18998
1571
26904
2596
10612
2607
18212
1475
26758
2299
27729
3737
1071
968
1063
2004
3074
2307
2259
2385
3186
1038
1448
1214
922

62
4367
4231
4004
3991
3886
3626
3483
3304
2838
2803
2734
1894
1705
1562
3105
2761
2748
2352
2080
2016
1967
1714
1618
1536
546
513
1051
2400
1120
1983
1290
1362
1490

1155
1144
1114
1083
1041
984
959
950
938
897
812
603
3149
754
654
1008
568
817
545
1834
1087
1721
1376

